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It has recently been estimated that each year, more than seven
million babies worldwide are born with either a congenital
abnormality or a genetic disease.1 Hemoglobinopathies are
the commonest autosomal hereditary disorders and present a
major public health problem in India. The overall prevalence
of the -thalassemia trait is 2.78% but this varies from 1.48
to 3.64% in different states of India2 compared to the carrier
frequency in Brazil (1%).3 Recently we reported that the carrier
frequency of the -thalassemia gene with the IVS1-5 (G→C)
mutation in western districts of Odisha, India is 3.75%.4,5
In India, the IVS1-5 (G→C)  mutation is the most common
-thalassemia mutation. However, the IVS1-5 (G→C)  mutation
along with other mutations, including IVS1-1 (G→T),  Cd41/42
(-TCTT), Cd 8/9 and a 619 base pair deletion, accounts for
>90% of mutations causing -thalassemia. In Brazil, the Cd 39
(C→T)  mutation is the most prevalent cause of -thalassemia
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reserved.followed by the IVSI-6 (T→C),  and IVSI-110 (G→A)  mutations.6
A map  showing zonal distribution of -thalassemia mutations
in India is depicted in Figure 1.
The Veer Surendra Sai Medical College and Hospital, Burla,
Odisha is a tertiary care referral hospital catering for west-
ern Odisha as well as eastern districts of Chhattisgarh state.
Under a comprehensive sickle cell care program, we screen
outpatient and hospitalized cases in the Institute for Sickle
Cell Disease and other hemoglobinopathies at the Sickle Cell
Clinic and Molecular Biology Laboratory.
Compound heterozygotes for -thalassemia and struc-
tural hemoglobin (Hb) variants usually present with a severe
form of the disease. Here, we report a case, a com-
pound heterozygote for the -thalassemia mutation IVS1-5
(G→C)  and Indian deletion-inversion G(A)0-thalassemia. Sambalpur, Odisha, India.
(HbVar ID-1038) from the district of Bargarh in the state of
Odisha, India. The molecular structure of the Indian deletion-
inversion [G(A)0-thal] is caused by a major rearrangement
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his is the ﬁrst case report of such a case from eastern India.
ase  report
n 18-year-old female patient (height 147 cm and weight 40 kg)
elonging to the ‘Chasa’ caste was admitted to the Depart-
ent of Medicine of Veer Surendra Sai Medical College and
ospital, Burla, Odisha, India with severe anemia, but with
o history of any other medical complaints. Her Hb level was
 g/dL at the time of admission to the hospital. After a trans-
usion of three blood units, the Hb level reached 7.8 g/dL. The
rythrocyte sedimentation rate was 12 mm/h. Other parame-
ers of blood indices after the blood transfusion were white
9lood cell count (WBC): 10.9 × 10 cells/L; red blood cells (RBC):
.35 × 106/L; hematocrit (HCT): 23.9%; mean corpuscular vol-
me (MCV): 71.7 fL; mean cell hemoglobin (MCH): 20.6 pg;
ean cell hemoglobin concentration (MCHC): 29.0 g/dL; andistribution of -thalassemia mutations.
platelets (PLT): 149 × 109/L. Peripheral blood smear exam-
ination showed microcytic, hypochromic anemia, marked
anisopoikilocytosis, many  microcytes, few macrocytes and
fragmented RBCs. Staining by the Kleihauer–Betke method
demonstrated pancellular distribution of fetal hemoglobin
(Hb F). Ultrasonography examination revealed hepatomegaly
(16.5 cm)  and splenomegaly (14.5 cm). An X-ray of chest (P-A
view) and X-ray of both hip joints (A-P view) showed no abnor-
malities.
Automated high-performance liquid chromatography
using the -Thalassemia Short Program on Bio-Rad Variant-II
system showed various fractions of Hb with a raised level of
Hb F (84.6%) and an Hb A2 concentration of 6.9% (Figure 2).
Parents’ studies revealed that her mother had a high Hb F
level (13%) whereas her father had high Hb A2 level (5.2%).
All hematological parameters of the case and her parents
are shown in Table 1. Screening for the common molecular
determinants of raised Hb F, the Indian deletion-inversion
G(A)0-thalassemia and hereditary persistence of fetal
Hb (HPFH) was performed by gap-polymerase chain reaction
(PCR) using primers and protocol as described previously.7
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Figure 2 – High performance liquid chromatogram in the case of compound heterozygous state for -thalassemia with
)0IVS1-5 (G→C)  mutation and Indian deletion-inversion G(A
at follow-up).
Common Indian -thalassemia mutations were conﬁrmed
by multiplex ampliﬁcation refractory mutation system
(ARMS)-PCR using a previously described protocol.4 More-
over, alpha globin gene deletions (−3.7 and −4.2) were
investigated by gap-PCR.8 The DNA study showed father
as heterozygous for the IVS1-5(G→C) mutation and mother
as a G(A)0-thalassemia carrier. The gel picture for
Indian deletion-inversion G(A)0-thalassemia is shown in
Figure 3. Alpha-thalassemia was not observed in any of them.
Written informed consent was obtained from the patient
along with her parents and the study was approved by Institu-
tional Ethics Committee of Veer Surendra Sai Medical College
and Hospital, Burla, Odisha, India.
Discussion
+ -Thalassemia is the second most common hemoglobinopa-
thy in our clinic’s population. We have reported earlier
the clinical and molecular characteristics of G(A)0-
thalassemia in heterozygous as well as in compoundthalassemia (chromatogram one year after hospitalization
heterozygous states with Hb S. In Hb S/G(A)0-thalassemia
cases, the patients had repeated painful crises along with
histories of blood transfusions.9 Indian deletion-inversion
G(A)0-thalassemia in the heterozygous form has been
reported in western India in the state of Maharashtra.10
Recently, Pandey et al. described seven cases with Indian
deletion-inversion G(A)0-thalassemia, of which three
cases were co-inherited with -thalassemia with the IVS1-
5(G→C) mutation.11 These three cases had low values of both
Hb A2 (3.2%, 2.8%, and 2.7%) and Hb F (21.3%, 10.7% and 20.3%)
compared to the 6.9% and 84.6% of Hb A2 and Hb F, respec-
tively in the current case. Their three cases were transfusion
dependent and showed moderate anemia. Our case is the ﬁrst
case of compound heterozygote state of -thalassemia with
IVS1-5(G→C) mutation and G(A)0-thalassemia with mild
phenotype from eastern India. In this patient, there was no
other probable cause to explain the acute episode of anemia
in history or investigations. As parvovirus B19 is not investi-
gated in our institution, this may well be a cause of the anemia
in this patient. The milder clinical presentation is likely due
to the association of a milder +-thalassemia allele with high
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Figure 3 – Agarose gel electrophoresis for the detection of -thalassemia with IVS1-5 (G→C)  mutation (ARMS PCR) and
Indian deletion-inversion G(A)0 thalassemia (GAP-PCR). *I: index; M:  mother; F: father; L: ladder. Detection of
-thalassemia with IVS1-5 (G→C)  mutation by ARMS PCR (Line A1, Line A4 and Line A6 for normal -globin gene, and Line
A2, Line A5 and Line A7 for IVS1-5 [G→C]  mutation). Detection of Indian deletion-inversion G(A)0 thalassemia by
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oAP-PCR (Line B1, Line B2 and Line B3 for Breakpoint-A, and
b F level (84.6%). Our observation of homogeneous F cell
istribution and an elevated Hb F level in peripheral blood,
s in agreement to the report of Waye et al. in an African-
merican with compound heterozygosity of a Black form
f (A)0-thalassemia and the −29 (A→G)  +-thalassemia
utation.12 We  only investigated two types of -thalassemia
−3.7 and −4.2), the most prevalent in India. Another form of
-thalassemia may be a factor for milder clinical presentation
f the patient.
Table 1 – Hematological investigations in the case of
compound heterozygous state for -thalassemia with
IVS1-5 (G→C)  mutation and Indian deletion-Inversion
G(A)0 thalassemia with her parents.
Parameters Index (follow-up)
One year after
hospitalization
Father Mother
Complete blood count
WBC (103/L) 13 13.9 9.2
RBC (106/L) 4.81 3.87 3.67
Hemoglobin (g/dL) 8.0 8.3 7.8
HCT (%) 32.3  30.4 29.7
MCV (fL) 67.2 78.6 80.9
MCH (pg) 16.6 21.4 21.3
MCHC (g/dL) 24.8 27.3 26.3
Platelets (103/L) 125 312 188
Fractions of Hb variants by HPLC
Hb A0 (%) 10.3 83 76.2
Hb A2 (%) 6.9 5.2 2.8
Hb F (%) 84.6 0.3 13
WBC: white blood cells; RBC: red blood cells; HCT: hematocrit;
MCV: mean cell volume; MCH: mean cell hemoglobin; MCHC:
mean cell hemoglobin concentration; HPLC: high-performance liq-
uid chromatography.
re B4, Line B5 and Line B6 for Breakpoint-B).
The Indian subcontinent has a heterogeneous popula-
tion with different hemoglobinopathies. These Hb disorders
should be included in the prenatal diagnosis of patients with
severe or mild thalassemia. The characterization of these
hemoglobinopathies will facilitate a prevention and control
program of hemoglobinopathies including thalassemia in this
region.
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